Oct 10 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. AND MOFFITT CANCER CENTER EXTEND COLLABORATION ON IMMUNOTHERAPY, INCLUDING STUDY OF L-DOS47 WITH PD-1/PD-L1 INHIBITORS
* HELIX BIOPHARMA CORP - IT HAS EXTENDED ITS COLLABORATION AGREEMENT WITH MOFFITT CANCER CENTER FOR AN ADDITIONAL YEAR